A randomized phase 2 trial of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with erlotinib in EGFR wild-type NSCLC patients

Authors :: Keunchil Park
Manuel Modiano
Enriqueta Felip
Frances A. Shepherd
Akin Atmaca
Mariano Provencio
Christopher J. Kripas
Maria Q. Baggstrom
Wael A. Harb
Ariel Lopez-Chavez
Akos Czibere
Jhanelle E. Gray
Robert C. Doebele
Byoung Chul Cho
David M. Jackman
Lecia V. Sequist
Gavin MacBeath
Manuel Cobo
Source :: Journal of Clinical Oncology. 32:8051-8051
Publication Year :: 2014
Publisher :: American Society of Clinical Oncology (ASCO), 2014.
Abstract: 8051 Background: Heregulin induced activation of ErbB3 has been implicated as a mechanism of resistance to many targeted therapies such as EGFR-TKIs in preclinical models. MM-121 is a monoclonal an...

Subjects :: Cancer Research
animal structures
medicine.drug_class
business.industry
Wild type
Pharmacology
Monoclonal antibody
respiratory tract diseases
Oncology
Monoclonal
Cancer research
medicine
Neuregulin
ERBB3
Erlotinib
business
medicine.drug

Full Text Access

Tools